Drugs / IBRX-042
IBRX-042
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05976828 | Jun 2024 → Sep 2027 expected | human papillomavirus-related squamous cell carcinoma | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07628062 | Jul 2026 → Dec 2030 expected | oropharynx squamous cell carcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBRX-042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07628062 ↗ |
| Known as | hAd5-HPV Vaccine | “hAd5-HPV Vaccine (IBRX-042)” NCT07628062 ↗ |
| Known as | IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine) | “IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine)” NCT05976828 ↗ |
| Route | Subcutaneous | “IBRX-042 administered subcutaneously” NCT07628062 ↗ |